Effect of asymmetric dimethylarginine (ADMA) on heart failure development

Xiaoyu Liu; Lei Hou; Dachun Xu; Angela Chen; Liuqing Yang; Yan Zhuang; Yawei Xu; John T. Fassett; Yingjie Chen

doi:10.1016/j.niox.2016.02.006

Effect of asymmetric dimethylarginine (ADMA) on heart failure development

Xiaoyu Liu, Lei Hou, Dachun Xu, Angela Chen, Liuqing Yang, Yan Zhuang, Yawei Xu, John T. Fassett, Yingjie Chen

Research output: Contribution to journal › Review article › peer-review

46 Scopus citations

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases that limits nitric oxide bioavailability and can increase production of NOS derived reactive oxidative species. Increased plasma ADMA is a one of the strongest predictors of mortality in patients who have had a myocardial infarction or suffer from chronic left heart failure, and is also an independent risk factor for several other conditions that contribute to heart failure development, including hypertension, coronary artery disease/atherosclerosis, diabetes, and renal dysfunction. The enzyme responsible for ADMA degradation is dimethylarginine dimethylaminohydrolase-1 (DDAH1). DDAH1 plays an important role in maintaining nitric oxide bioavailability and preserving cardiovascular function in the failing heart. Here, we examine mechanisms of abnormal NO production in heart failure, with particular focus on the role of ADMA and DDAH1.

Original language	English (US)
Pages (from-to)	73-81
Number of pages	9
Journal	Nitric Oxide - Biology and Chemistry
Volume	54
DOIs	https://doi.org/10.1016/j.niox.2016.02.006
State	Published - Apr 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Inc.

Keywords

Asymmetric dimethylarginine
Dimethylarginine dimethylaminohydrolase-1
Heart failure
Nitric oxide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.niox.2016.02.006

http://europepmc.org/articles/pmc5017793

Find It

Find It at U of M Libraries

Cite this

@article{a938e2fa50c4480e94a9775e161d739c,

title = "Effect of asymmetric dimethylarginine (ADMA) on heart failure development",

abstract = "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases that limits nitric oxide bioavailability and can increase production of NOS derived reactive oxidative species. Increased plasma ADMA is a one of the strongest predictors of mortality in patients who have had a myocardial infarction or suffer from chronic left heart failure, and is also an independent risk factor for several other conditions that contribute to heart failure development, including hypertension, coronary artery disease/atherosclerosis, diabetes, and renal dysfunction. The enzyme responsible for ADMA degradation is dimethylarginine dimethylaminohydrolase-1 (DDAH1). DDAH1 plays an important role in maintaining nitric oxide bioavailability and preserving cardiovascular function in the failing heart. Here, we examine mechanisms of abnormal NO production in heart failure, with particular focus on the role of ADMA and DDAH1.",

keywords = "Asymmetric dimethylarginine, Dimethylarginine dimethylaminohydrolase-1, Heart failure, Nitric oxide",

author = "Xiaoyu Liu and Lei Hou and Dachun Xu and Angela Chen and Liuqing Yang and Yan Zhuang and Yawei Xu and Fassett, {John T.} and Yingjie Chen",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.niox.2016.02.006",

language = "English (US)",

volume = "54",

pages = "73--81",

journal = "Nitric Oxide - Biology and Chemistry",

issn = "1089-8603",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Effect of asymmetric dimethylarginine (ADMA) on heart failure development

AU - Liu, Xiaoyu

AU - Hou, Lei

AU - Xu, Dachun

AU - Chen, Angela

AU - Yang, Liuqing

AU - Zhuang, Yan

AU - Xu, Yawei

AU - Fassett, John T.

AU - Chen, Yingjie

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases that limits nitric oxide bioavailability and can increase production of NOS derived reactive oxidative species. Increased plasma ADMA is a one of the strongest predictors of mortality in patients who have had a myocardial infarction or suffer from chronic left heart failure, and is also an independent risk factor for several other conditions that contribute to heart failure development, including hypertension, coronary artery disease/atherosclerosis, diabetes, and renal dysfunction. The enzyme responsible for ADMA degradation is dimethylarginine dimethylaminohydrolase-1 (DDAH1). DDAH1 plays an important role in maintaining nitric oxide bioavailability and preserving cardiovascular function in the failing heart. Here, we examine mechanisms of abnormal NO production in heart failure, with particular focus on the role of ADMA and DDAH1.

AB - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases that limits nitric oxide bioavailability and can increase production of NOS derived reactive oxidative species. Increased plasma ADMA is a one of the strongest predictors of mortality in patients who have had a myocardial infarction or suffer from chronic left heart failure, and is also an independent risk factor for several other conditions that contribute to heart failure development, including hypertension, coronary artery disease/atherosclerosis, diabetes, and renal dysfunction. The enzyme responsible for ADMA degradation is dimethylarginine dimethylaminohydrolase-1 (DDAH1). DDAH1 plays an important role in maintaining nitric oxide bioavailability and preserving cardiovascular function in the failing heart. Here, we examine mechanisms of abnormal NO production in heart failure, with particular focus on the role of ADMA and DDAH1.

KW - Asymmetric dimethylarginine

KW - Dimethylarginine dimethylaminohydrolase-1

KW - Heart failure

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=84960344008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960344008&partnerID=8YFLogxK

U2 - 10.1016/j.niox.2016.02.006

DO - 10.1016/j.niox.2016.02.006

M3 - Review article

C2 - 26923818

AN - SCOPUS:84960344008

SN - 1089-8603

VL - 54

SP - 73

EP - 81

JO - Nitric Oxide - Biology and Chemistry

JF - Nitric Oxide - Biology and Chemistry

ER -

Effect of asymmetric dimethylarginine (ADMA) on heart failure development

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this